NCT03054519 (PERMET) is a Phase 3 clinical trial of Metformin in Peripheral Artery Disease, sponsored by Northwestern University.

Who is sponsoring NCT03054519?

NCT03054519 is sponsored by Northwestern University.

What drugs are being tested in NCT03054519?

Interventions in NCT03054519: Metformin, Placebo.

What condition does NCT03054519 study?

NCT03054519 studies Peripheral Artery Disease.

Is NCT03054519 still recruiting?

NCT03054519 is currently completed. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT03054519: PERMET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improve PAD PERformance With METformin

Completed Phase 3 Last updated 15 April 2026

What this trial tests

Phase 3 trial testing Metformin in Peripheral Artery Disease in 203 participants. Completed in 1 November 2025.

Timeline

23 May 2017

Primary endpoint
20 August 2025

1 November 2025

Quick facts

Lead sponsor	Northwestern University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	203
Start date	23 May 2017
Primary completion	20 August 2025
Estimated completion	1 November 2025
Sites	5 locations across United States

Drugs / interventions tested

Metformin (metformin) — full drug profile →
Placebo

Conditions studied

Peripheral Artery Disease — all drugs for Peripheral Artery Disease →

Sponsor

Northwestern University

Who can join

18 and older, any sex, with Peripheral Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Estrogen-related receptor alpha is an AMPK-regulated factor that promotes ischemic muscle revascularization and recovery in diet-induced obese mice.
Sopariwala DH, Rios AS, Park MK, Song MS, et al · · 2022 · cited 18× · PMID 36089981 · DOI 10.1096/fba.2022-00015
MetfOrmin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC): randomized clinical trial protocol.
Reitz KM, Althouse AD, Forman DE, Zuckerbraun BS, et al · · 2023 · cited 6× · PMID 36681798 · DOI 10.1186/s12872-023-03047-8
Mitochondrial fatty acid beta-oxidation: a possible therapeutic target for skeletal muscle lipotoxicity in peripheral artery disease myopathy.
Bradley CE, Fletcher E, Wilkinson T, Ring A, et al · · 2024 · cited 3× · PMID 38741727 · DOI 10.17179/excli2024-7004
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial.
McDermott MM, Domanchuk KJ, Tian L, Zhao L, et al · · 2026 · cited 1× · PMID 41205146 · DOI 10.1001/jama.2025.21358
Medical therapies, comorbid conditions, and functional performance in people with peripheral artery disease enrolled in clinical trials between 2004 and 2021.
Nayak P, Polonsky T, Tian L, Greenland P, et al · · 2023 · cited 1× · PMID 36588397 · DOI 10.1177/1358863x221145533
Community-based recruitment with ankle brachial index testing to identify peripheral artery disease participants for randomized clinical trials.
McDermott MM, Cetlin MD, Domanchuk KJ, Xu S, et al · · 2026 · PMID 42035974 · DOI 10.1016/j.ahj.2026.107450
Gastrocnemius Myofiber Type and Mitochondrial Alterations Associated With Peripheral Artery Disease Severity.
Kosmac K, Wang RD, Stewart J, Kaur P, et al · · 2025 · PMID 41051228 · DOI 10.1093/function/zqaf047

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Peripheral Artery Disease

Currently open trials in the same condition.

NCT07374601 — The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease · recruiting
NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT07012070 — Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers · NA · recruiting

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03054519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03054519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing